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The Epstein – Barr virus (EBV) EBNA-1 protein has a central role in the maintenance of a latent EBV infection and is the
only virus-encoded protein expressed in all EBV-associated tumors. EBNA-1 is required for replication of the episomal form
of the latent viral genome and transactivates the latency C and LMP-1 promoters. The mechanisms by which EBNA-1
performs these functions are not known. Here we describe the cloning, expression, and characterization of a cellular protein,
P32/TAP, which strongly interacts with EBNA-1. We show that P32/TAP is expressed at high levels in Raji cells and is
synthesized as a proprotein of 282 amino acids (aa) that is posttranslationally processed by a two-step cleavage process
to yield a mature protein of 209 aa. It has been previously reported that P32/TAP is expressed on the cell surface. Our
transient expression assays detected full-length P32/TAP (1–282 aa) in the cytoplasm while mature P32/TAP protein
localized to the nucleus. Three lines of evidence support P32/TAP interaction with EBNA-1. First, in the yeast two-hybrid
system we mapped two interactive N-terminal regions of EBNA-1, aa 40–60 and aa 325–376, each of which contains
arginine–glycine repeats. These regions interact with the C-terminal half of P32/TAP. Second, the full-length cytoplasmic
P32/TAP protein can translocate nuclear EBNA-1 into the cytoplasm. Third, P32/TAP co-immunoprecipitated with EBNA-1.
We have confirmed that a Gal4 fusion protein containing the C-terminal region of P32/TAP (aa 244–282) transactivates
expression from a reporter containing upstream Gal4-binding sites. Deletion of the P32/TAP interactive regions of EBNA-
1 severely diminished EBNA-1 transactivation of FRTKCAT in transient expression assays. Our data suggest that interaction
with P32/TAP may contribute to EBNA-1-mediated transactivation. q 1997 Academic Press
INTRODUCTION EBNA-1 is a DNA-binding protein which binds to a cluster
of sites in EBV that together constitute the plasmid origin
Epstein–Barr virus (EBV) is a ubiquitous gamma her- of viral replication, oriP (Rawlins et al., 1985; Yates et al.,
pes virus that is associated with several human dis- 1984), and to two sites immediately downstream of the
eases, including infectious mononucleosis, Burkitt’s latency Qp (Nonkwelo et al., 1996; Rawlins et al., 1985;
lymphoma, nasopharyngeal carcinoma, mixed cellularity
Schaefer et al., 1995; Smith and Griffin, 1992). The crystal
Hodgkins’ disease, and lymphoproliferative disease in
structure of the EBNA-1 DNA-binding domain bound to
immunocompromised hosts such as AIDS and transplant
DNA has been solved (Bochkarev et al., 1996). Purified
patients (Miller, 1990; Rickinson and Kieff, 1996). In
EBNA-1 lacks detectable enzymatic functions such as atransgenic mice, expression of EBNA-1 can induce tu-
DNA-dependent ATPase or helicase (Frappier andmors (Wilson et al., 1996; Wilson and Levine, 1992). The
O’Donnell, 1991b; Middleton and Sugden, 1992), whichEBNA-1 protein has a centrol role in the maintenance of
are important activities for other viral origin-binding, repli-latent EBV infection, and it is the only virus-encoded pro-
cation proteins such as UL9 of herpes simplex (Brucknertein required for replication of the episomal form of the
et al., 1991), T antigen of simian virus 40 (Wold et al.,EBV genome (Yates et al., 1985). EBNA-1 is a phospho-
1987), and E1 of bovine papillomavirus type 1 (Yang etprotein (Hearing and Levine, 1985) with an unusual struc-
al., 1993). The exact mechanism whereby EBNA-1 contri-ture; it is separated into N- and C-terminal domains
butes to oriP DNA replication is unclear. EBNA-1–EBNA-[amino acids (aa) 1 –89 and 327–641] by a glycine– gly-
1 interactions promote both intramolecular DNA loopingcine–alanine repeat sequence. The size of EBNA-1 var-
(Frappier and O’Donnell, 1991a; Su et al., 1991) and inter-ies considerably in individual EBV-containing cell popula-
molecular DNA interactions (Goldsmith et al., 1993;tions (from 69 to 94 kDa), depending on the number of
Mackey et al., 1995) which may generate a DNA structurethese repeats within the protein (Heller et al., 1982).
favorable for replication initiation. EBNA-1 may also be
involved in the attachment of ori-P to the nuclear matrix
1 To whom correspondence and reprint requests should be (Jankelevich et al., 1992).
addressed at Department of Pharmacology and Molecular Sciences, In cotransfection assays, EBNA-1 acts as a transcrip-Johns Hopkins School of Medicine, 725 N. Wolfe Street, Balti-
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qmail.bs.jhu.edu. Sugden and Warren, 1989; Yates and Camiolo, 1988); it
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can transactivate heterologous promoters when multiple were cloned from pRA362 (Ambinder et al., 1990) and
pWS61 (Shah et al., 1992).EBNA-1-binding sites are present within the target plas-
mid (Reisman and Sugden, 1986; Wysokenski and Yates, Plasmid pYW51, a modified SG5 vector (Stratagene,
La Jolla, CA) expressing an amino-terminal Flag epitope1989) and contributes to down-regulation of the native
EBV Qp (Sample et al., 1992; Sung et al., 1994) and to (Eastman Kodak Co., New Haven, CT), was used to make
three Flag-tagged P32/TAP expression plasmids; P32/up-regulation of the latency Cp and LMP-1p (Gahn and
Sugden, 1995; Puglielli et al., 1996; Schlager et al., 1996; TAP(1-282)(pYW59) was constructed by cloning a BglII
fragment from a P32/TAP cDNA clone 64 into the BamHISugden and Warren, 1989). However, EBNA-1 lacks a
specific transcriptional activation domain. Fusion of dif- site of pYW51. Two P32/TAP mutations, P32/TAP(33–
282) (pYW76) and P32/TAP(81–282) (pYW84), wereferent parts of EBNA-1 to the GAL4 DNA-binding domain
failed to generate a chimera capable of activating GAL4 cloned by digesting the P32/TAP cDNA with PstI and
HindIII, blunt ending with Klenow or T4 DNA polymerase,reporters (M-R. Chen, unpublished results; Horner et al.,
1995). Therefore the mechanism of EBNA-1-mediated adding BamHI linkers, and ligating into pYW51. A full-
length P32/TAP BamHI/BglII fragment was also removedtransactivation is also unclear. The inability to detect an
intrinsic transcriptional activation function prompted us from cDNA clone 64 and ligated into the BamHI site of
pSG5(YW164). Using similar PCR methods, we con-to explore the possibility that a cellular protein(s) inter-
acting with EBNA-1 might contribute to its transactivation structed EBNA-1 variants by inserting EBNA-1 frag-
ments into another modified SG5 plasmid, pMRC69ability. A yeast two-hybrid screen for interacting proteins
identified P32/TAP, a protein that has been previously (Chen et al., 1994), to generate pMRC72[E1(D102-325)],
pYW47[E1(D102-325, D40-60)], pYW48[E1(D102-381)],described by several different investigators and that has
been implicated in splicing (Honore et al., 1993; Krainer and pYW102[E1(376-641)].
The target plasmids used for CAT assays, 51Gal4-et al., 1990), transactivation (Yu et al., 1995a,b), and re-
ceptor functions (Eggleton et al., 1994, 1995; Ghebrehi- TKCAT and FRTKCAT, have been described previously
(Hsieh and Hayward, 1995; Reisman and Sugden, 1986).wet et al., 1994, 1995). To address the biological rele-
vance of the EBNA-1 interaction we examined the pro- The P32/TAP Gal4 fusion plasmid pYW61 contains a full-
length P32/TAP, and pYW62 contains a domain from aacessing and cellular localization of P32/TAP and mapped
the interaction to the two arginine–glycine-rich domains 244 to aa 282, which was generated by PCR amplification
with primers LGH1637 and LGH2179.within EBNA-1. Deletion of these regions abrogated the
transcriptional activity of EBNA-1, implicating P32/TAP
as a possible mediator of EBNA-1-dependent transacti- Yeast two-hybrid screen
vation.
Saccharomyces cerevisiae Y190 and Y187 and yeast
plasmids pAS1-CYH2 and pACTII were obtained from
MATERIALS AND METHODS
Stephen Elledge (Durfee et al., 1993). A human lympho-
cyte cDNA library in which the cDNAs are joined to thePlasmid constructions
Gal4 activation domain (aa 768–881) in pACT was pur-
chased from Clontech (Palo Alto, CA). Y190 plasmidsThe plasmids used in the yeast two-hybrid assay were
cloned into the vector pAS1-CHY2 (Durfee et al., 1993). were transformed to Trp prototrophy by the method of
Schiestl and Geitz (1989) with pAS-EBNA-1, which con-The different EBNA-1 segments were generated by PCR
amplification and, after restriction enzyme digestion, the tained EBNA-1 fused to the Gal4 DNA-binding domain
(1–147) in pAS1-CYH2. A single colony was grown in SCproducts were fused in-frame to the Gal4 DNA-binding
domain. Expression of the fusion proteins was confirmed Trp0 medium and transformed with library DNA using
single-strand DNA as carrier. Aliquots were taken fromby Western blotting with anti-Gal4 antibody (Upstate Bio-
technology). Gal4-E1(D102-325) (pYW18), which contains each transformation mix and plated on SC medium lack-
ing tryptophan and leucine to determine the transforma-a full-length EBNA-1 with a deletion from aa 102 to 325,
was PCR-amplified from p367 (Yates and Camiolo, 1988) tion efficiency. The transformation mix was then plated
on 15-cm petri dishes containing SC medium lackingwith primers LGH734 and LGH312; pWS41[Gal4-E1
(D102-381)] was amplified from p385(d145) (a gift from tryptophan, leucine, and histidine but including 40 mM
3-AT (Sigma) and incubated at 307 for 5–7 days. His/John Yates) with primers LGH312 and LGH734; pYW44
[Gal4-E1(1-89; D40-60)] and pYW95[Gal4-E1(D102-325, colonies were then screened for b-galactosidase activity
using a filter lift assay (Breeden and Nasmyth, 1985).D40-60)] were amplified from p378d1GA (a gift from John
Yates) with primers LGH2147, LGH901, and LGH2148; Colonies were transferred onto nitrocellulose filters, per-
meabilized by freezing in liquid nitrogen for 5 sec, andpYW96 [Gal4 - E1(1-89 ) ] , pYW97 [Gal4 - E1( 85-641 ) ], and
pYW98[Gal4-E1(376-641)] were amplified from p367 with thawed at room temperature. Filters were then overlaid
on Whatman 3MM papers saturated with Z-buffer/X-galprimers LGH2147, LGH2149, LGH2150, and LGH2148;
pYW11[Gal4-E1(459-641)] and pYW42[Gal4-E1(408-641)] solution (60 mM Na2HPO4r7H2O, 40 mM NaH2PO4rH2O,
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10 mM KCl, 1 mM MgSO4r7H2O, 35 mM b-mercaptoetha- with PBS. The cells were incubated in cold PBS con-
taining 0.2% Triton 100 for 15 min on ice and then rinsednol, 0.4 mg/ml X-gal), and incubated at 307. The time
required for color development was 4–6 hr. The positive twice with PBS. Primary antibodies were diluted in PBS
and were typically reacted for 1 hr at 377. To removecDNAs were recovered from yeast using SC medium
selection and transformed into DH5a via electroporation excess antibody, the slides were washed four times in
PBS. Fluorochrome-conjugated secondary antibodiesusing a Bio-Rad GenePulser. The positive clones were
sequenced using Sequenase 2.0 (U.S. Biochemicals) ac- were reacted in the same manner. Excess secondary
antibodies were removed by four washes in PBS. Thecording to the manufacturer’s specifications. Sequence
analysis and homology searches were performed using processed slides were then mounted with mounting me-
dium (Sigma). The prepared slides were examined byBLAST (NIH) and GeneWorks (IntelliGenetics, Inc.). Pro-
tein interaction was quantified by determining b-galac- confocal optics and an Olympus inverted microscope.
tosidase activity: Cultures (2.5 ml) were grown in the
Co-immunoprecipitationappropriate selection medium to an OD600 of 1.0. Cells
were then prepared and permeabilized as described by Cos-1 cells were transfected with 8 mg each of Flag-
the library supplier (Clontech). Cell pellets were resus- tagged P32/TAP and the different EBNA-1 constructions.
pended and o-nitrophenyl-b-D-galactoside substrate was Forty-eight hours after transfection the cells were lysed
added. The amount of liberated O-nitrophenol was deter- in 500 ml of isotonic lysis buffer (142.5 mM KCl, 5 mM
mined at OD420 . MgCl2 , 10 mM HEPES, pH 7.2, 1 mM EGTA, pH 8.0, and
0.2% NP-40). One hundred microliters of the extract was
Transient expression and Western immunoblot
kept for direct analysis of the proteins present. Four hun-
analysis
dred microliters of the extract was incubated with anti-
Flag rabbit antibody (Santa Cruz, Inc.) overnight at 47Vero, Cos-1, 293, and CV-1 cells were maintained in
followed by the addition of 100 ml of Protein A –Sepha-Dulbecco’s modified Eagle’s medium plus 10% fetal calf
rose (Pharmacia, Sweden). After incubation for 3 hr atserum at 377 in 5% CO2 and were transfected using cal-
47, these samples, along with the samples for direct anal-cium phosphate-BES [N*N-bis (2-hydroxyethyl)-2-ami-
ysis, were subjected to 10% SDS–PAGE and transferrednoethanesulfonic acid]-buffered saline (Chen and Oka-
to a nitrocellulose membrane. The individual proteinsyama, 1987). Cells were lysed 60 hr after transfection in
were detected with monoclonal antibody EBNA.OT1x and21 sample buffer [50 mM Tris, 4% sodium dodecyl sulfate
ECL (Amersham, England). Co-immunoprecipitation of(SDS), 20% glycerol, 0.04% bromophenol blue, 200 mM
endogenous P32/TAP was performed similarly usingdithiothreitol] at 2 1 104 cells/ml and were sonicated
293 cells transfected with 8 mg of wild-type EBNA-1briefly. The lysate was electrophoresed through a 10%
DNA. The cell extract was immunoprecipitated withpolyacrylamide gel. After blocking in Tris-buffered saline
EBNA.OT1x monoclonal antibody and after immunoblot-(TBS), 5% nonfat dry milk, 0.1% Tween 20 for 1 hr and
ting, proteins were detected with anti-P32 antibody (Ghe-washing with TBS, 0.1% Tween 20, the filter was then
brehiwet et al., 1994).incubated with Flag M2 monoclonal antibody (Kodak
Inc.), anti-P32/TAP antibody (gift of B. Ghebrehiwet (Ghe-
CAT assaybrehiwet et al., 1994)), or EBNA-1 monoclonal antibody
EBNA.OT1x (Chen et al., 1993) in TBS, 0.1% Tween 20 at CV-1 cells were plated in six-well cluster dishes at 2
room temperature for 1 hr. The filter was washed three 1 105 cells per well the day before transfection. Cells
times for 15 min in TBS–Tween and then incubated in a were harvested 40 hr after transfection and assays for
1:5000 dilution of alkaline phosphatase-conjugated goat CAT were performed as previously described (Ling et al.,
anti-mouse antibody or anti-rabbit antibody. The filter 1993).
was washed three times and developed with an ECL kit
(Amersham, England) followed by exposure to Kodak X- RESULTS
ray film.
EBNA-1 interacts with P32/TAP in a yeast two-hybrid
Immunofluorescence assay assay
Evidence that EBNA-1 interacts with P32/TAP emergedVero cells were plated at approximately 0.8 1 105 cells
per well onto glass tissue culture chamber slides (Nunc). from analyses of a yeast two-hybrid screen. Yeast ex-
pressing a Gal4 DNA-binding domain fusion of the full-DNA transfections were performed as described above,
with a total of 2 mg of DNA transfected per well. At 24 hr length EBNA-1 in which the glycine–alanine repeat
region was deleted were transformed with a human lym-posttransfection, cells were washed twice in phosphate-
buffered saline (PBS) and then incubated with PBS con- phocyte cDNA library. Approximately 1.5 million trans-
formants were placed under selection. Of the 63 cDNAtaining 3% paraformaldehyde (pH 8.0) for 10 min at room
temperature. The fixative was removed by two washes plasmids whose products interacted specifically with
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TABLE 1 between amino acids 325 and 376 of EBNA-1. Each of
these regions contains arrays of arginine and glycineStructure of P32/TAP cDNA Clones Selected in a Yeast
residues.Two-Hybrid Screen for Interaction with EBNA-1a
P32/TAP EBNA-1 EBNA-1 P32/TAP (aa 1–282) is cleaved twice within the N-
(aa)b (1–641D102 – 325) (459–641) SNF-1 P53 terminus to form the mature protein
1 – 282 / 0 0 0 Krainer et al. (1991) viewed P32/TAP as a full-length
19 – 282 / 0 0 0 protein of 209 amino acids with a CTG (Leu) initiator
22 – 282 / 0 0 0
codon. However, Honore et al. (1993) observed that P32/25 – 282 / 0 0 0
TAP is produced as a proprotein of 282 amino acids with35 – 282 / 0 0 0
a conventional ATG start codon. These authors further43 – 282 / 0 0 0
46 – 282 / 0 0 0 demonstrated that the 209-amino-acid protein is the ma-
53 – 282 / 0 0 0 ture form that is produced by posttranslational pro-
55 – 282 / 0 0 0
cessing of the 282-amino-acid proprotein.60 – 282 / 0 0 0
To examine P32/TAP processing, a series of P32/TAP64 – 282 / 0 0 0
variants tagged with the Flag epitope at the N-terminus71 – 282 / 0 0 0
103– 282 / 0 0 0 was constructed in a pSG5 background. Extracts of trans-
fected Cos-1 cells were analyzed by Western blot with
a The specificity of interaction was tested by cotransforming yeast
anti-Flag monoclonal antibody and anti-P32/TAP mono-Y190 with these P32 cDNAs and EBNA-1 (1–641D102–325), EBNA-1
clonal antibody (a gift from Berhane Ghebrehiwet, SUNY).(459– 641), pAS/SNF1, or pAS/P53. b-Galactosidase activity was mea-
As shown in the blot probed with anti-P32/TAP antibodysured by a filter lift assay, which resulted in blue color (/), indicating
interaction or white color (0), indicating no interaction. in Fig. 3A, the P32/TAP (aa 1–282) construct expressed
b The 25 interactive clones identified represented 13 separate mainly the full-length P32/TAP which is about 39 kDa, as
cDNAs.
well as two smaller forms of 35 and 32 kDa. P32/TAP
(aa 33–282) expressed two polypeptides, the smaller of
which was the same size as the 32-kDa product gener-EBNA-1, 31 were partially sequenced and 25 of these
ated from P32/TAP (aa 1–282) and the same size aswere found to match the published sequence of P32/
endogenous P32/TAP from Raji cells. These smaller poly-TAP (Table 1). The different 5* termini of the P32/TAP
peptides were not observed in the blot probed with anti-cDNA clones indicate that the EBNA-1 interaction do-
Flag antibody (shown in Fig. 3B), indicating that themain is located after amino acid 103 of P32/TAP. P32
smaller polypeptides were formed by removal of the N-was initially identified as a protein in a HeLa cell extract
terminus of P32/TAP. P32/TAP (aa 81–282) expressedthat copurified with the SF2/ASF splicing factor (Honore
only one band which was similar in size to endogenouset al., 1993; Krainer et al., 1990, 1991) while TAP was
P32/TAP from Raji cells. These observations are inidentified by affinity chromatography as a protein inter-
agreement with those of Honore et al. (1993) in sug-acting with the HIV Tat transactivator and cloned from a
gesting that the mature form of the P32/TAP protein isMolt 3 T-cell library (Yu et al., 1995b). P32/TAP is highly
produced by posttranslational processing of the 282-conserved and the mouse homolog YL2 (Luo et al., 1994)
amino-acid proprotein. Furthermore, we demonstratehas 92% identity with human P32/TAP (Fig. 1). P32/TAP
that there are two separate cleavage sites in the N-termi-transcripts are expressed in most human tissues (Yu et
nal region of P32/TAP located between aa 1 and 33 andal., 1995b) and in a variety of different cell lines (Deb and
between aa 33 and 71. The band detected in the vectorDatta, 1996; Luo et al., 1994; Yu et al., 1995b).
lane may represent a more rapidly migrating form of the
endogenous P32/TAP in Cos-1 cells. P32/TAP expres-Mapping of P32/TAP interaction domains in EBNA-1
sion has been described in both lymphoid and non-
The unexpectedly large number of P32/TAP clones
lymphoid cell lines. In agreement with these reports, we
whose products interacted with EBNA-1 prompted further
detected P32/TAP by immunoblot analysis in a variety of
investigation into the nature of the association between
B-cell lines including CA46, DG75, Akata, IB4, P3HR-1,
P32/TAP and EBNA-1. To map the EBNA-1 domain inter-
and B95-8 (data not shown).
acting with P32/TAP, a series of EBNA-1 deletions was
made. Each EBNA-1 variant was cloned as a GAL4 DNA- Intact and processed forms of P32/TAP differ in their
binding domain fusion and transformed into yeast strain intracellular localization
Y190 containing the plasmid expressing P32/TAP as a
Gal4 activation domain fusion. The EBNA-1–P32/TAP in- P32/TAP has been reported to be a complement C1q
subunit-binding protein that is expressed on the plasmateraction was quantitated using a lacZ assay (Fig. 2).
The results revealed two separate P32/TAP interaction membrane (Ghebrehiwet et al., 1994), a protein that co-
purifies with the SF2 splicing factor (Honore et al., 1993;domains located between amino acids 40 and 60 and
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FIG. 1. Amino acid sequence comparison of P32 homologs. YL2 is a mouse isolate and is 208 aa in length (Luo et al., 1994) and P32/gC1qR/
TAP proteins are human isolates (Ghebrehiwet et al., 1994; Honore et al., 1993; Krainer et al., 1991; Yu et al., 1995b) and are 282 (P32/C1qR) and
279 (TAP) amino acids long. Identical amino acids are boxed.
FIG. 2. Mapping P32/TAP interactive domains in EBNA-1. Diagrammatic representation of the different Gal4–EBNA-1 fusion constructions tested.
Yeast Y190 plasmids were cotransformed with each of the Gal4–EBNA-1 constructions and Gal4-P32/TAP [Gal4 activation domain II (aa 768–881)–
P32/TAP (aa 1–282)]. The black boxes indicate interaction domains for P32/TAP. The results of liquid culture assays to quantitate b-galactosidase
activity are summarized on the right.
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with transfected full-length EBNA-1, as demonstrated by
the immunoprecipitation assay shown in Fig. 5B.
P32/TAP (aa 1–282) relocates EBNA-1 into the
cytoplasm
Additional evidence for a physical interaction between
P32/TAP and EBNA-1 came from a visualization of the
intracellular distribution of EBNA-1 in P32/TAP cotrans-
fected cells. Anti-EBNA-1 monoclonal antibody was used
to detect EBNA-1, and anti-Flag rabbit antibody was used
to detect P32/TAP (Fig. 6). Figure 6D shows single stain-
ing of individually transfected Vero cells expressingFIG. 3. Expression of endogenous and Flag-tagged transfected P32/
EBNA-1, mature P32/TAP (aa 81–282), and full-lengthTAP. Cos-1 cells were transfected with the indicated Flag-tagged P32/
TAP constructions or the vector pYW51 (a pSG5-based vector express- P32/TAP (aa 1–282). Figures 6A and 6B show that P32/
ing the Flag epitope). The positive control was Raji cell extract. Cell TAP and EBNA-1 cotransfected Vero cells stained with
extracts were electrophoresed through SDS–polyacrylamide gels and anti-P32/TAP antibody (red) and anti-EBNA-1 antibody
transferred to nitrocellulose filters, and protein expression was visual-
(green). Diffuse nuclear P32/TAP (aa 81–282) and EBNA-ized using anti-P32/TAP monoclonal antibody or Flag M2 monoclonal
1 colocalized in the nucleus. The cytoplasmic P32/TAPantibody and the ECL detection system. The positions of molecular
weight size markers are indicated. (aa 1–282) translocated most of the nuclear EBNA-1 pro-
tein to the cytoplasm and perfectly colocalized with
EBNA-1 in spots surrounding the nucleus. P32/TAP does
Krainer et al., 1991), an HIV Rev interactive protein (Luo not interact indiscriminantly with nuclear proteins since
et al., 1994), and an HIV TAT interactive protein (Yu et P32/TAP (aa 1–282) did not relocate the human cytomeg-
al., 1995b). In order to investigate the intracellular distri- alovirus nuclear regulatory protein, IE1 (Fig. 6C).
bution of P32/TAP, we transfected Vero cells with Flag-
The P32/TAP interaction domains of EBNA-1 appeartagged P32/TAP (aa 1 –282) and two Flag-tagged deletion
to be critical for EBNA-1-dependent transactivationvariants expressing aa 33–282 and aa 81–282. The
transfected cells were immunostained with both anti- EBNA-1 can activate transcription from heterologous
Flag and anti-P32/TAP antibodies. Surprisingly, three dif- promoters when at least seven EBNA-1-binding sites
ferent staining patterns were observed (Fig. 4). P32/TAP
(aa 1–282) remained in the cytoplasm and formed con-
densed globules that were concentrated around the nu-
cleus. P32/TAP (aa 33 –282) showed diffuse staining over
both the cytoplasm and the nucleus. P32/TAP (aa 81 –
282) localized predominantly to the nucleus and had a
diffuse staining pattern. In order to eliminate the possibil-
ity that N-terminal tagging might affect processing of the
protein, we cloned the full-length P32/TAP in pSG5 with-
out the Flag epitope and found similar results when the
cells were stained with anti-P32/TAP antibody (data not
shown). It has been reported that the mature form of P32/
TAP comprises aa 71 –282 (Honore et al., 1993). P32/
TAP (aa 81–282) is only 10 aa smaller than this mature
polypeptide and gives predominantly nuclear staining,
thus strongly suggesting that mature P32/TAP is a nu-
clear form.
P32/TAP co-immunoprecipitates with EBNA-1
P32/TAP was isolated because of its strong binding
to EBNA-1 in a yeast two-hybrid assay. To determine
FIG. 4. Cellular localization of P32/TAP. Immunofluorescence photo-whether P32/TAP can interact with EBNA-1 in mamma-
micrographs of Vero cells transfected with Flag-tagged P32/TAP ex-lian cells, co-immunoprecipitation assays were per-
pression constructions. Transfected Vero cells were fixed and incu-formed (Fig. 5). Both cytoplasmic P32/TAP (aa 1 – 282)
bated with Flag M2 monoclonal antibody followed by FITC-conjugated
and nuclear P32/TAP (aa 81–282) co-immunoprecipi- goat anti-mouse immunoglobulin G antiserum. (A) Flag-tagged P32/
tated with full-length EBNA-1 in cotransfected cells (Fig. TAP (aa 1–283). (B) Flag-tagged P32/TAP (aa 33–283). (C) Flag-tagged
P32/TAP (aa 81–283).5A, lanes 2 and 3). Endogenous P32/TAP also interacted
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complete amino-terminus containing both domains abro-
gated the ability of EBNA-1 to activate FRTKCAT.
DISCUSSION
EBNA-1 acts as the origin-binding protein for oriP repli-
cation during latency but lacks detectable enzymatic ac-
tivities such as DNA-dependent ATPase or helicase,
which are intrinsic to other viral origin-binding replication
proteins such as E1 of papillomavirus, UL9 of herpes
simplex virus, or T antigen of simian virus 40. Further-
more, EBNA-1 acts as a transactivator of viral latency
promoters but lacks a detectable activation domain. DNA
FIG. 5. Co-immunoprecipitation of EBNA-1 and P32/TAP. (A) Cos-1 binding is essential for both replication and transactiva-
cells were transfected with 8 mg of each of the Flag-tagged P32/TAP tion functions (Ambinder et al., 1991; Kirchmaier and Sug-
and EBNA-1 constructions. 48 hr after transfection the cells were lysed den, 1997; Polvino-Bodnar and Schaffer, 1992). DNA bind-and the extract was incubated with anti-Flag M2 monoclonal antibody
ing by EBNA-1 produces significant structural alterationsfollowed by the addition of 100 ml of Protein A–Sepharose. The immu-
in the DNA (Frappier and O’Donnell, 1991a, 1992; Gold-noprecipitates were subjected to 10% SDS–PAGE and transferred to
a nitrocellulose membrane. The individual proteins were detected with smith et al., 1993; Hearing et al., 1992; Hsieh et al., 1993;
the monoclonal antibody EBNA.OT1x and ECL. Lane 1, EBNA-1; lane Mackey et al., 1995; Su et al., 1991) which are anticipated
2, EBNA-1 plus P32/TAP (aa 1 – 282); lane 3, EBNA-1 plus P32/TAP (aa to contribute to both replication and transactivation activi-81 –282); lane 4, P32/TAP (aa 1–282); lane 5, P32/TAP (aa 81–282).
ties and EBNA-1 also binds to RNA (Snudden et al., 1994).(B) Co-immunoprecipitation of endogenous P32/TAP from 293 cells
However, it seems likely that there are additional contri-transfected with 8 mg of wild-type EBNA-1.
butions made by EBNA-1 and the most likely scenario
is that these activities would be mediated by EBNA-1
interacting proteins. The cellular protein P32/TAP was(Wysokenski and Yates, 1989) are added and can acti-
vate transcription from the latency C and LMP-1 promot- isolated in a two-hybrid screen for such interacting part-
ners.ers which are positioned approximately 10 kb from the
oriP EBNA-1-binding sites in the EBV genome. However, P32/TAP is a previously described protein whose pub-
lished properties are somewhat difficult to reconcile.EBNA-1 lacks a detectable transactivation domain. It has
been reported that P32/TAP contains a transcriptional P32/TAP was originally isolated as a component of a
biochemically purified splicing complex that containedactivation domain that interacts with the general tran-
scription factor TFIIB (Yu et al., 1995a). To determine p32 and p33 polypeptides (Krainer et al., 1991). Subse-
quent work showed that the p33 protein SF2/ATF had allwhether P32/TAP contributes to EBNA-1 transactivation,
we first confirmed that P32/TAP did indeed contain an the properties of a functional splicing factor and P32/
TAP was not required for splicing activity (Mayeda et al.,activator domain. In agreement with the published report
we found that a Gal4 fusion with intact P32/TAP (aa 1 – 1992), leaving the relevance of the original association
an open question. Other associations between P32/TAP282) showed no appreciable activation. However, an im-
munofluorescence assay showed that this fusion protein and splicing have been made but in each case these
are indirect. P32/TAP was detected in a yeast two-hybridwas retained in the cytoplasm despite the presence of
the nuclear localization signal within Gal4 (1–147). On screen for proteins that interacted with the HIV-1 Rev
protein (Luo et al., 1994). Rev binds to the Rev responsethe other hand, a Gal4 fusion that localized to the nucleus
and contained P32/TAP (aa 244–282) gave 40- to 50- element in HIV RNAs and is believed to influence RNA
splicing. In the presence of Rev, singly spliced and un-fold activation of a cotransfected reporter containing five
copies of the Gal4-binding site upstream of the promoter spliced genomic viral RNAs are efficiently transported to
the cytoplasm. In transient expression assays, cotrans-(Fig. 7). We then generated three EBNA-1 variants, each
of which had the gly-gly-ala repeat region (aa 102 – 325) fection of P32/TAP with Rev led to increased activity of
a CAT reporter in which the CAT gene was present withindeleted in addition to specific deletions of: (i) the first
EBNA-1 P32/TAP interaction domain (aa 40–60); (ii) the an intron and could be expressed only from an unspliced
transcript. However, these results would potentially alsosecond P32/TAP interaction domain (aa 325–381); and
(iii) the entire amino-terminus, including both P32/TAP be compatible with transcriptional activation by Rev-teth-
ered P32/TAP. Also detected in a yeast two-hybrid screeninteraction domains (Fig. 8). In cotransfection assays,
parental EBNA-1(D102-325) transactivated the CAT ex- was an association with another viral protein, the product
of ORF P, an HSV ORF transcribed in latent infectionpression from the FRTKCAT reporter containing the
EBNA-1-binding sites from the ori-P family of repeats (Bruni and Roizman, 1996). In IF assays ORF P colocal-
ized with a splicing factor, SC35, but the concurrent pres-approximately 10- to 30-fold (Fig. 8). Deletion of either
of the P32/TAP interaction domains or deletion of the ence of P32/TAP was not examined.
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FIG. 6. Confocal photomicrographs showing EBNA-1 colocalization with P32/TAP in transfected cells. (A) Vero cells cotransfected with EBNA-1
(Daa 102–325) and Flag-tagged P32/TAP (aa 81–282). EBNA-1 was detected by EBNA.OT1x mAb and FITC-conjugated sheep anti-mouse antibody
(green fluorescence on the left). Flag-tagged P32/TAP was detected using anti-Flag rabbit antibody followed by Texas red-conjugated horse anti-
rabbit second antibody (red fluorescence in the middle). The yellow staining in the confocal overlay on the right indicates colocalization of the two
proteins. (B) Vero cells cotransfected with EBNA-1 (Daa 102–325) and Flag-tagged P32/TAP (aa 1–282). EBNA-1 (green fluorescence on the left)
and Flag-tagged P32/TAP (red fluorescence in the middle) colocalize (yellow) in the cytoplasm in the confocal overlay on the right. (C) Vero cells
cotransfected with HCMV IE1 and Flag-tagged P32/TAP (aa 1–282). IE1 was detected by anti-IE1 mAb and FITC-conjugated sheep anti-mouse
antibody (green fluorescence on the left). Flag-tagged P32/TAP is shown in the middle (red fluorescence). The confocal overlay on the right shows
no evidence for colocalization. (D) Vero cells transfected with (left) EBNA-1 (Daa 102–325); (middle) Flag-tagged P32/TAP (aa 81–282), and (right)
Flag-tagged P32/TAP (aa 1 – 282).
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P32/TAP had been reported to be processed from the
full-length 282-amino-acid protein to a mature form that
lacks the amino-terminal 73 amino acids. We demon-
strated that this processing results from two independent
cleavage events and used immunofluorescence assays
to examine the intracellular localization of the different
forms of P32/TAP. Interestingly, while the mature form of
the protein localized to the nucleus, the full-length protein
appeared in the cytoplasm. Thus it is plausible that P32/
TAP could function as a plasma membrane receptor and,
after processing, relocate to the nucleus to serve a sec-
ond gene regulatory function. There is precedent for such
a mechanism. The Notch receptor is a large transmem-
brane protein that participates in intercellular signaling
events that determine cell fate decisions (Artavanis-Tsa-
konas et al., 1995). The cleaved intracellular domain of
Notch, NotchIC, localizes to the nucleus and activates
FIG. 7. P32/TAP contains a transcriptional activation domain. Tran- expression of genes containing CBF1-binding sites in
sient expression assay in Vero cells which received 1 mg of the 51 their regulatory sequences by binding to the repression
Gal4TKCAT reporter plasmid and 2 mg of the indicated Gal4-P32/TAP
domain of DNA-bound CBF1 (Hsieh et al., 1996, 1997;effector DNAs. The results shown are an average of two experiments
Jarriault et al., 1995). The EBV EBNA-2 protein also inter-with the standard deviation indicated.
acts with CBF1 and functions, in part, by mimicking
NotchIC (Hsieh and Hayward, 1995). Another example is
the sterol regulatory element-binding proteins (SREBPs),
P32/TAP has been identified as a transcriptional acti- which attach to the endoplasmic reticulum. This tran-
vator (Yu et al., 1995b). P32/TAP was isolated by affinity scription factor is released from the membrane in re-
chromatography as a protein interacting with HIV-1 Tat. sponse to sterols by two sequential cleavages and the
Gal4-P32/TAP fusion constructions were created and the liberated domain translocates to the nucleus and acti-
presence of a transcriptional activation domain was dem- vates genes controlling cholesterol synthesis (Sakai et
onstrated. This domain was negatively charged and mu- al., 1996).
tation of two hydrophobic residues (leucines) within the While a case can be made for a gene regulation func-
domain abolished the activation function, indicating that tion for P32/TAP, the question remains as to the biologi-
the activation observed was not merely a nonspecific
charge effect. The potential for P32/TAP to function as
an activator was strengthened by the demonstration that
P32/TAP interacted in vitro with the basal transcription
factor TFIIB (Yu et al., 1995a).
While connections between P32/TAP and either splic-
ing or transactivation would be consistent with a gene
regulation function in the nucleus, the identification of
P32/TAP as a plasma membrane receptor (Eggleton et
al., 1995; Ghebrehiwet et al., 1994; Peerschke et al., 1994)
initially appears contradictory. Ghebrehiwet et al. (1994)
isolated from Raji cells a protein, gC1qR, that binds to
the globular heads of gC1q molecules and inhibits com-
plement-mediated lysis of sheep red blood cells. They
used the amino acid sequence of the purified protein to
design PCR primers and cloned the P32/TAP cDNA from
a B-cell library. The recombinant protein had the proper-
ties of the purified protein in terms of size, sequence,
and ability to inhibit lysis of sheep red blood cells. P32/
FIG. 8. Deletion of the P32/TAP interaction domains abolishes EBNA-TAP does not contain a recognizable transmembrane
1-mediated transactivation. Transient expression assay in CV-1 cellsdomain but it has also been found to bind to hyaluronic
which were transfected with the reporter FRTKCAT (2 mg) and the
acid (Deb and Datta, 1996), a high-molecular-weight non- EBNA-1 constructions diagrammed in the lower panel. Deletion of ei-
sulfated glycosaminoglycan, and this may be relevant to ther of the P32/TAP interaction domains (aa 40–60 or aa 325–381) is
associated with loss of transactivation.its apparent surface expression.
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Bruckner, R. C., Crute, J. J., Dodson, M. S., and Lehman, I. R. (1991). Thecal relevance of the interaction between P32/TAP and
herpes simplex virus 1 origin binding protein: A DNA helicase. J.EBNA-1. Relevance can usually be determined by corre-
Biol. Chem. 266, 2669–2674.
lating loss of interaction with loss of function but these Bruni, R., and Roizman, B. (1996). Open reading frame P—A herpes
experiments are not completely decisive in the case of simplex virus gene repressed during productive infection encodes
a protein that binds a splicing factor and reduces synthesis of viralEBNA-1. The interaction mapped to the two arginine–
proteins made from spliced mRNA. Proc. Natl. Acad. Sci. USA 93,glycine-regions of EBNA-1 and deletion of either of these
10423–10427.regions severely impaired EBNA-1 transactivation, a re-
Chen, C., and Okayama, H. (1987). High-efficiency transformation of
sult which is consistent with previous reports (Puglielli mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745–2752.
et al., 1996; Yates and Camiolo, 1988). The aa 325 – 376 Chen, M.-R., Middeldorp, J. M., and Hayward, S. D. (1993). Separation
of the complex DNA binding domain of EBNA-1 into DNA recognitionarginine–glycine domain is required for RNA binding by
and dimerization subdomains of novel structure. J. Virol. 67, 4875–EBNA-1 (Snudden et al., 1994) for both intrastrand DNA
4885.looping and interstrand DNA linking as well as for EBNA-
Chen, M.-R., Zong, J.-C., and Hayward, S. D. (1994). Delineation of a
1 oligomerization (Goldsmith et al., 1993; Laine and Frap- sixteen amino acid sequence that forms a core DNA recognition
pier, 1995; Mackey et al., 1995), and hence loss of trans- motif in the Epstein–Barr virus EBNA-1 protein. Virology 205, 486–
495.activation function upon loss of this domain may be oc-
Deb, T. B., and Datta, K. (1996). Molecular cloning of human fibroblastcurring for a variety of reasons. The aa 40–60 region of
hyaluronic acid-binding protein confirms its identity with P-32, a pro-EBNA-1 has been associated with DNA linking but not
tein co-purified with splicing factor SF2. J. Biol. Chem. 271, 2206–
with any other function, and P32/TAP binding to this re- 2212.
gion is of interest. The loss of transactivation that occurs Durfee, T., Becherer, K., Chen, P.-L., Yeh, S.-H., Yang, Y., Kilburn, A. E.,
Lee, W.-H., and Elledge, S. J. (1993). The retinoblastoma protein asso-on removal of this region is provocative but cannot un-
ciates with the protein phosphatase type 1 catalytic subunit. Genesequivocally be linked to loss of P32/TAP binding. The
Dev. 7, 555–569.two arginine–glycine domains of EBNA-1 interacted in-
Eggleton, P., Ghebrehiwet, B., Coburn, J. P., Sastry, K. N., Zaner, K. S.,
dependently with P32/TAP in the yeast two-hybrid assay and Tauber, A. I. (1994). Characterization of the human neutrophil
and the EBNA-1 deleted for the aa 40–60 region retains C1q receptor and functional effects of free ligand on activated neutro-
phils. Blood 84(5), 1640–1649.the second aa 325 –376 region. However, it is possible
Eggleton, P., Ghebrehiwet, B., Sastry, K. N., Coburn, J. P., Zaner, K. S.,that while each EBNA-1 domain is sufficient for protein–
Reid, K. B., and Tauber, A. I. (1995). Identification of a gC1q-bindingprotein tethering to P32/TAP in the yeast assay system,
protein (gC1q-R) on the surface of human neutrophils. Subcellular
the presence of both regions is necessary for a functional localization and binding properties in comparison with the cC1q-R.
interaction that is capable of mediating transactivation J. Clin. Invest. 95(4), 1569–1578.
Frappier, L., and O’Donnell, M. (1991a). Epstein–Barr virus nuclearas would be required in the cotransfection CAT assays.
antigen 1 mediates a DNA loop within the latent replication originP32/TAP is a protein whose processing and intracellular
of Epstein–Barr virus. Proc. Natl. Acad. Sci. USA 88, 10875–10879.localization are suggestive of a regulatory function and
Frappier, L., and O’Donnell, M. (1991b). Overproduction, purification,
the possibility that it may be contributing to EBNA-1- and characterization of EBNA-1, the origin binding protein of EBV. J.
mediated transactivation is intruiging. Biol. Chem. 266, 7819–7826.
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